Comparison of oral absorption models for pregabalin: usefulness of transit compartment model
Taegon Hong,1 Seunghoon Han,2,3 Jongtae Lee,2,3 Sangil Jeon,4 Dong-Seok Yim2,3 1Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, 2Department of Clinical Pharmacology and Therapeutics, Seoul St Mary’s ...
Jeon S, Hong T, Lee J, Yim DS, Han S
core
Updated Estimates of Agreement Between Dispensed Medications and Forensic Toxicology in Sweden
ABSTRACT Purpose To present updated estimates from a nationwide Swedish study comparing dispensed medications with forensic toxicological findings (2006–2013), following re‐evaluation of the toxicology dataset to address periods with non‐uniform analytical detection and inconsistent testing.
Heidi Taipale +3 more
wiley +1 more source
ABSTRACT Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disorder with multisystem involvement that causes progressive muscular weakness and cardiorespiratory dysfunction. The first comprehensive recommendations regarding anesthetic management are now almost 20 years old and, in the interval, DMD care has evolved.
Fabrizio Racca +4 more
wiley +1 more source
Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report
Burak Kulaksizoğlu,1,2 Hüseyin Kara,1,2 Berkan Bodur,1,2 Murat Kuloğlu1,2 1Department of Psychiatry, Akdeniz University School of Medicine, Antalya, Turkey; 2Akdeniz University, Alcohol and Substance Addiction Treatment and Research Center, Antalya,
Kulaksizoğlu B +3 more
core
Impacts of a Statewide Prescription Drug Monitoring Program—Healthcare Practitioner Perspectives
ABSTRACT This study examined the perceived impacts of New South Wales' (NSW) statewide prescription drug monitoring program (PDMP; “SafeScript NSW”) from the perspective of prescribers and pharmacists, using a qualitative descriptive design. Fourteen prescribers and pharmacists who were users of NSW's PDMP completed semi‐structured interviews between ...
Emma Tay +3 more
wiley +1 more source
Multicentre, 2×2 factorial, randomised, open-label trial of neuromodulators and cough control therapy for refractory or unexplained chronic cough: the FORTITUDE trial protocol. [PDF]
Kum E +21 more
europepmc +1 more source
Ruo-Wen Chen,1,2 Hui Liu,2 Jian-Xiong An,1,2 Xiao-Yan Qian,2 Yi-De Jiang,2 Doris K Cope,3 John P Williams,3 Rui Zhang,1 Li-Na Sun1 1Department of Anesthesiology, Weifang Medical University, Weifang City, Shandong, 2Department of Anesthesiology, Pain ...
Liu H +8 more
core
Efficacy and safety of mirogabalin in patients with fibromyalgia: protocol for a multicentre, Prospective, Randomised, Open-label, Blinded Endpoint (PROBE) study. [PDF]
Liu M +13 more
europepmc +1 more source
Marcelo J Martins,1 Caroline Paiva Matos Oliveira Martins,2 Lucas J Castro-Alves,3 Gabriel Nascimento Jesus,4 Guilherme Oliveira Campos,5 Breno Barbosa Cerqueira Sacramento,4 Leonardo Ferrari Borges,6 Carlos Augusto Bastos Mello,6 Rodrigo Leal Alves,5 ...
Nascimento Jesus G +9 more
core
Real world treatment patterns among patients with painful diabetic peripheral neuropathy in the United States. [PDF]
Schuster NM +6 more
europepmc +1 more source

